体外診断薬（IVD）の世界市場：動向と市場最新情報：2025年

当レポートは、経済と世界の不確実性が続く中、ダイナミックな体外診断薬（IVD）市場に関する最新の洞察を提供しています。

2024年、IVD市場は拡大を続け、COVID-19検査収益の減少にもかかわらず、ほとんどのセグメントで成長が見られます。AIによるイノベーション、規制の変化、世界のヘルスケア支出の変化が競合情勢を形成し、IVD分野の回復力を強めています。

業界が注目し、IVDの将来において重要な役割を果たすと予想される主な成長分野は以下の通りです：

当レポートは、世界の体外診断薬（IVD）市場について調査し、市場促進要因と主な業界動向、IVDイノベーションを形成する新製品開発、競合情勢の考察と主要企業の動向、新たな成長機会と戦略的成長分野などをまとめています。

目次

第1章 世界のIVD市場の最新情報-2025年4月

• IVD市場の需要と成長
• COVID-19診断市場
• COVID-19による市場セグメントへの影響

第2章 製品の動向と新開発

• 液体生検
• 質量分析
• 免疫測定
• 分子
• 個別化医療
• 有色人種
• シーケンシング
• 抗原/抗体
• 分子

第3章 IVD市場における主要企業の結果

• 厳選された競争リーダーの最新情報
• 2024年第4四半期、2025年第1四半期のM&A活動
• Abbott Laboratories
• Becton Dickinson and Co
• bioMerieux SA
• Danaher Corporation
• Dexcom, Inc
• Exact Sciences
• QuidelOrtho Corporation
• Roche Diagnostic
• Siemens Healthineers
• Sysmex Corporation
• Thermo Fisher Scientific

第4章 新たな機会

Kalorama Information's "In Vitro Diagnostic (IVD) Trends and Market Update, 2025" provides the latest insights into the dynamic IVD market amid ongoing economic and global uncertainties. Published twice a year-first in April 2025 and again in Q4 2025, following the release of Kalorama's annual 1,600-page study, "The Worldwide Market for In Vitro Diagnostics (IVD), 18th Edition"-this report serves both as a standalone resource and a companion to Kalorama's annual flagship IVD analysis.

In 2024, the IVD market continued to expand, with most segments experiencing growth, despite the decline in COVID-19 testing revenues. AI-driven innovations, regulatory shifts, and changes in global healthcare spending are shaping the competitive landscape, reinforcing the resilience of the IVD sector.

Key growth areas attracting industry attention and that are anticipated to play a significant role in the future of IVD include:

This report delivers timely and actionable intelligence, covering:

• Market drivers and major industry trends
• New product developments shaping IVD innovation
• Competitive landscape insights and activities of key players
• Emerging opportunities and strategic growth areas

With a commitment to delivering precise and up-to-date market intelligence, Kalorama Information continues to provide industry stakeholders with critical data and expert analysis to navigate the ever-evolving IVD landscape.

Table of Contents

Chapter 1: Worldwide IVD Market Update - April 2025

• IVD Market Demand and Growth
  • Figure 1-1: Segment Performance Commentary, Q1-Q4 2024
  • Table 1-1: Global In Vitro Diagnostic Sales, by Product Market, 2024 ($ million) [Blood bank molecular - NAT Screens, Blood grouping/typing, Circulating tumor cells, Clinical Chemistry, Coagulation (PT/INR), Coagulation, molecular, D-dimer, Hematology - Core Lab, Histology/cytology, HPV, molecular, Immunoassays - non-isotopic (Immuno - Infectious disease, Other immune, Immuno - Blood bank screening, Drugs of Abuse, Diabetes HbA1c, lab), Mass Spectrometry, Microbiology (ID/AST), Microbiology (molecular), Microbiology - Mass Spectrometry, Nucleic acid assays/genetic tests, Other (transplant testing, other, etc.), POC, OTC diabetes, POC, OTC other, POC, professional/hospital]
  • Figure 1-2: Quarterly IVD Segment Performance, by Segment, Q1 2024 - Q4 2024 ($ million) [Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other]
  • Figure 1-3: IVD Segment Performance, Total Market Value, 2024 ($ million) [Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other]
• COVID-19 Diagnostic Markets
  • Table 1-2: COVID-19 Product Sales, 2024 ($ million) [Immunoassay (Antigen, Serology), Molecular, Rapid]
• Effect of COVID-19 on Market Segments
  • Table 1-3: IVD Market Excluding and with COVID-19, 2024 ($ million)
  • Figure 1-4: IVD Market Distribution, by Segment, 2024 (%) [IVD Market Excluding COVID-19 Assays and Instruments, COVID-19 Assays and Instruments]
  • Figure 1-5: IVD Market by COVID-19 and non-COVID Markets, Quarterly Performance, 2024 ($ million) [IVD Market Excluding COVID-19 Assays and Instruments, COVID-19 Assays and Instruments]
  • Table 1-4: Global In Vitro Diagnostic Market, YoY Growth 2023-2024 (%) [Blood bank molecular - NAT Screens, Blood grouping/typing, Circulating tumor cells, Clinical Chemistry, Coagulation (PT/INR), Coagulation, molecular, D-dimer, Hematology - Core Lab, Histology/cytology, HPV, molecular, Immunoassays - non-isotopic (Immuno - Infectious disease, Other immune, Immuno - Blood bank screening, Drugs of Abuse, Diabetes HbA1c, lab), Mass Spectrometry, Microbiology (ID/AST), Microbiology (molecular), Microbiology - Mass Spectrometry, Nucleic acid assays/genetic tests, Other (transplant testing, other, etc.), POC, OTC diabetes, POC, OTC other, POC, professional/hospital]
  • Figure 1-6: Global In Vitro Diagnostic Market - YoY Growth 2023-2024 (%) [Blood bank molecular - NAT Screens, Blood grouping/typing, Circulating tumor cells, Clinical Chemistry, Coagulation (PT/INR), Coagulation, molecular, D-dimer, Hematology - Core Lab, Histology/cytology, HPV, molecular, Immunoassays - non-isotopic (Immuno - Infectious disease, Other immune, Immuno - Blood bank screening, Drugs of Abuse, Diabetes HbA1c, lab), Mass Spectrometry, Microbiology (ID/AST), Microbiology (molecular), Microbiology - Mass Spectrometry, Nucleic acid assays/genetic tests, Other (transplant testing, other, etc.), POC, OTC diabetes, POC, OTC other, POC, professional/hospital]

Chapter 2: Product Trends and New Developments

• Liquid Biopsy
• Mass Spectrometry
• Immunoassay
• Molecular
• Personalized Medicine
• POC
• Sequencing
• Antigen/Antibody
• Molecular

Chapter 3: Top IVD Market Participant Results

• Selected Competitive Leader Updates
  • Figure 3-1: IVD Segment Growth by Leading Competitors, Change in Sales 2023-2024 (%) [Abbott Diagnostics, Becton Dickinson, bioMerieux, Danaher, Dexcom, QuidelOrtho, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific]
  • Figure 3-2: IVD Sales Changes in Market Distribution, 2021-2024 - Roche and Abbott Battle for #1 Spot (%) [Abbott Diagnostics, Becton Dickinson, bioMerieux, Danaher, Dexcom, Exact Sciences, Hologic, QuidelOrtho, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific, Werfen, Others]
  • Figure 3-3: Comparison of Total Diagnostic Sales for Abbott vs Roche, 2022-2024 ($ million)
• Q4 2024, Q1 2025 M&A Activity
  • Table 3-1: Q4 2024, Q1 2025 Merger and Acquisition Activity
• Abbott Laboratories
  • Table 3-2: Abbott Corporate Summary
• Becton Dickinson and Co
  • Table 3-3: Becton Dickinson Corporate Summary
• bioMerieux SA
  • Table 3-4: bioMerieux Corporate Summary
• Danaher Corporation
  • Table 3-5: Danaher Corporation Summary
• Dexcom, Inc
  • Table 3-6: Dexcom Corporate Summary
• Exact Sciences
  • Table 3-7: Exact Sciences Corporate Summary
• QuidelOrtho Corporation
  • Table 3-8: QuidelOrtho Corporate Summary
• Roche Diagnostic
  • Table 3-9: Roche Diagnostic Corporate Summary
• Siemens Healthineers
  • Table 3-10: Siemens Healthineers Corporate Summary
• Sysmex Corporation
  • Table 3-11: Sysmex Corporate Summary
• Thermo Fisher Scientific
  • Table 3-12: Thermo Fisher Scientific Corporate Summary

Chapter 4: New Opportunities

• Staffing Shortages
• LDT Update
• IVDR Compliance Deadline Approaches
  • Table 4-1: IVDR New Risk-based Classification System
• Telemedicine